Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00397

Submission Number:
00397
Commenter:
Mike Gindi
State:
California
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
Good Morning, America is a land of opportunities and options, freedom of speech and choice. I am a self made business man who owns several businesss and pharmacies. In the past five years since the Medicare and state Medicaid moving to HMO plans, it has been really tough on my business bottom line, but we have made it work finding clinical and superior service to service a volume based pharmacy. One of the toughest challenges in our business now is the PBM that are choking out profits and pushing us out of the business by plan pharmacy exclusions and directing the patients to their own pharmacies and minimizing reimbursement to be a loss so pharmacies can give up their scripts to the PBM pharmacy. On top of this CVS Caremark implements DIR fees that are uncontrollled by improving on any level or even minimum control. This purchase of CVS to Aetna is a pure market monopoly and greed. This merger will redefine the pharmacy market space and eliminate patient choice and decrease service and produce ridiculous patient outcome. Intern, that will increase health care cost. Please stop this purchase and thank you for your time and efforts. Mike Gindi